0%
Mr. Davis joined Akonni Biosystems in 2007 as the operations leader, and promoted to Vice President in 2008, then President in 2020.
Prior to joining Akonni, Mr. Davis served as Department and Technical Manager for General Dynamics’ Chemical Biological Radiological Nuclear and high yield Explosives (CBRNE) business unit. He served in similar roles and as operations manager and microbiologist with Veridian Corp and Pacific Sierra Research, where he worked with multidisciplinary teams to develop novel biological and chemical detection technologies for U.S. Defense and Homeland Security customers.
Mr. Davis has over 30 years of general management experience and 20 years of product development experience in integrated biosensors encompassing a broad range of disciplines including chemistry, biology, biomaterials, engineering, and chemical/biological defense.
As Vice President of Product Development at Akonni Biosystems, Dr. Cooney leads an innovative multi-disciplinary team of engineers and scientists in the pursuit of affordable, highly-informative diagnostics.
Dr. Cooney joined Akonni in 2007 and now draws upon more than 20 years of multi-disciplinary microfluidics and bioinstrumentation experience from both academia and industry.
Prior to joining Akonni, Dr. Cooney was an Engineering Manager at Northrop Grumman’s R&D Division and served as a technical liaison with the Manufacturing Division for the deployed Biohazard Detection System. There he also led the R&D of a microfluidic cartridge for isothermal assays for biodefense applications. One of these isothermal assays (Ionian NEAR assay) became the first CLIA-waved molecular diagnostic (Alere-i product line).
Dr Cooney’s other experiences can be viewed at https://www.linkedin.com/in/christopher-cooney-8628712/
Based on its recent analysis of the microarrays in molecular diagnostics (MDx) market, Frost & Sullivan recognizes Akonni Biosystems with the 2017 North American New Product Innovation Award.
Akonni’s integrated MDx system, TruDiagnosis®, is revolutionizing the point-of-care molecular testing market by enabling target detection from a variety of sample types. TruDiagnosis® is powered by TruArray®, a patented 3D gel-drop microarray technology for sample screening that instantly indicates the presence of disease markers in real time.
Download:
